| Product Unit Size | Cost | Quantity | Stock |
|---|
Azelnidipine is a dihydropyridine L-type Ca2+ channel blocker that exhibits antihypertensive, anti-atherosclerotic, and anti-inflammatory activities. Clinically, azelnidipine decreases blood pressure; it also decreases inflammatory cytokine levels and carotid intima-media thickness. Additionally, this compound preserves insulin signaling and glucose uptake in animal models of oxidative stress.
| Cas No. | 123524-52-7 |
|---|---|
| Purity | ≥98% |
| Formula | C33H34N4O6 |
| Formula Wt. | 582.66 |
| Chemical Name | 3-(1-Benzhydrylazetidin-3-yl) 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate |
| IUPAC Name | 3-[1-(Diphenylmethyl)-3-azetidinyl] 5-isopropyl 2-amino-6-methyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylate |
| Synonym | CS-905, RS-9054 |
| Solubility | 15 mg/ml in ethanol, 30 mg/ml in DMSO and DMF. sparingly soluble in aqueous buffers. |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Tawaramoto K, Kaneto H, Hashiramoto M, et al. Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study). Diabetol Metab Syndr. 2015 Sep 17;7:80. PMID: 26388951.
Tatsumi F, Kaneto H, Hashiramoto M, et al. Anti-hypertensive azelnidipine preserves insulin signaling and glucose uptake against oxidative stress in 3T3-L1 adipocytes. Endocr J. 2015;62(8):741-7. PMID: 26073866.
Chen BL, Zhang YZ, Luo JQ, et al. Clinical use of azelnidipine in the treatment of hypertension in Chinese patients. Ther Clin Risk Manag. 2015 Feb 24;11:309-18. PMID: 25750535.